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Abstract
In this paper a positive control law is designed for multi-input positive
systems that ensures asymptotic tracking of a desired output reference value.
This control law can be viewed as a generalization of another one proposed
in the literature for the control of the total mass in SISO compartmental
systems, but is suitable for a wider class of positive systems. The controller
proposed here is applied to the control of the depth of anesthesia (DoA),
by means of the administration of propofol and remifentanil, when using a
parameter parsimonious Wiener model recently introduced in the literature.
Its performance is illustrated by realistic simulations.
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1. Introduction
The goal of automatically controlled drug administration is to determine
the dosage to be administered to achieve and keep a certain e ect of a drug in
the patient. In this work, the primary goal is to track the level of the depth
of anesthesia, here measured by the bispectral index (BIS), which is trans-
formed into a problem of tracking the e ect concentration by inverting the
generalized Hill equation. This problem can be modeled as an output refer-
ence tracking problem. More specifically, after modeling the phenomenon in
question by a control system in which the control input is the dosage of drug
to be administered and the output is the corresponding e ect, one seeks a
control law that forces the system output to converge to the desired reference
value.
Since the quantities involved in this process are all nonnegative, this prob-
lem falls within the realm of positive systems. These systems have gained
increasing attention in the control literature during the last decades. See
for example Farina and Rinaldi [1], Haddad et al. [2], Roszak and Davison
[3], Roszak and Davison [4],Kaczorek [5], Willems [6], Soltesz et al. [7]. In
this latter reference, a controller by integral action together with a positivity
constraint was proposed, showing that the input is positive provided that
the integral gain ‘ > 0 is chosen su ciently small. This controller does not
presuppose a full knowledge of the model, however it does need the a pri-
ori knowledge of the steady-state gain matrix, in order to obtain a suitable
value for the integral gain ‘. This may take a long time to obtain in case the
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process poles are not fast enough. This constitutes a disadvantage for its use
in our application. The controller presented in this paper ensures reference
tracking independently from the positive value of the design parameter, with-
out requiring the knowledge of the steady-state gain matrix. Nevertheless, it
does require information about the model parameters and the corresponding
state. However, these parameters can be identified in a short preliminary
stage, and a state observer can be included in order to estimate the state
online. The control law, developed in this work, is considered to be nonlin-
ear, not due to use of nonlinear design methods, but rather because of the
imposition of positivity constraint on the control variable, which makes it a
nonlinear function of the state of the system.
In this paper we consider single output positive systems with multiple
inputs and design a nonlinear positive control law that ensures asymptotic
tracking of a desired output reference value. This control law can be viewed
as a generalization of the one proposed in Bastin and Provost [8] for the
control of the total mass in SISO compartmental systems. However, whereas
the control law in Bastin and Provost [8] is only designed for compartmental
systems, our control law is suitable for a wider class of positive systems as is
sustained by the new theoretical results presented in the paper (Section 2).
Our results prove to be useful for the control of the depth of anesthesia,
a problem that has lately deserved much attention. For instance, the work
developed in Soltesz et al. [7] presents two controllers in parallel for the DoA
of a patient based on a PID controller for the administration of propofol and
a proportional controller for the input of remifentanil. Here, we present one
single multi-output feedback controller for both drugs. A good overview of
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the underlying problem may be found in Dumont [9] and in the references
there in.
The proposed controller is applied to the control of the depth of anesthesia
by means of propofol and remifentanil using the recently proposed parameter
parsimonious Wiener model (see Silva et al. [10]). The performance of the
controller is analyzed by means of several simulations along with realistic
simulations relying on identified real patients data collected in the surgery
room during general anesthesia.
The present paper is structured as follows. In Section 2 a control law
is designed for output reference tracking in MISO positive systems. The
application of the corresponding controller in general anesthesia is presented
in Section 3. In Section 4 the performance of the proposed controller is
illustrated by means of several simulations, and the results of its application
in realistic simulated patients are presented in Section 5. Conclusions follow
in Section 6.
2. Output Reference Tracking for MISO Positive Systems
In this section the general problem of reference tracking for multi-input/single-
output (MISO) positive systems is presented. The application to the control
of anesthesia will be presented in Section 3.
2.1. Problem Description
Consider a positive system with m inputs and a single output described
by the state-space modelY_]_[ x˙(t) = Ax(t) +Bu(t)y(t) = Cx(t), (1)
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where A is a n◊n Meztler matrix, i.e., a matrix in which all the o -diagonal
components are nonnegative, and B and C are matrices with nonnegative
entries (see Godfrey [11]) of dimension n◊m and 1◊m, respectively. Here,
for short, in the sequel (1) is denoted by (A, B, C). Moreover, for a vector
v, the notations v Ø 0 (v > 0) and v Æ 0 (v < 0) mean that all its entries are
respectively positive (strictly positive) and negative (strictly negative). The
same applies to matrices.
Given a desired constant reference value yú for the output, a control law
u = Kx+ L is sought such that the closed-loop systemY_]_[ x˙(t) = (A+BK)x(t) +BLy(t) = Cx(t), (2)
has bounded trajectories and tracks the reference, i.e., such that its output
verifies limtæŒ y(t) = yú.
2.2. Controller design
Here we solve the problem of output reference tracking, by regarding it as
a problem of controlling the system to a level set  yú = {x œ Rn+ : Cx = yú}
in the state space, where Rn+ = {x œ Rn : x Ø 0}.
For this purpose, we first design an auxiliary control law, u˜, and then
impose positivity to u˜ in order to obtain a positive control input u. We also
make the following assumptions: (A1) A is stable, (A2) CB is a nonzero row
matrix and (A3) CA < 0.
Let
u˜(t) = ≠ECAx(t) + E⁄(yú ≠ y(t)), (3)
where ⁄ > 0 is a design parameter, and E is a column matrix with nonnega-
tive entries such that CBE = 1. Note that such a matrix always exists since
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CB has nonnegative entries, at least one of each is strictly positive. The
application of this control input leads to the closed-loop dynamics
x˙(t) = Ax(t) +B(E⁄(yú ≠ y(t))≠ ECAx(t)) (4)
which implies that
y˙(t) = Cx˙(t) = CAx(t) + ⁄(yú ≠ y(t))≠ CAx(t) (5)
= ≠⁄(y(t)≠ yú) (6)
and therefore
‰˙y(t)≠ yú = ≠⁄(y(t)≠ yú). (7)
Hence, y(t)≠ yú = e≠⁄t(y(0)≠ yú) and
lim
tæŒ y(t) = y
ú, (8)
which means that the output reference value is asymptotically tracked.
In the sequel it is shown that reference tracking can still be achieved even
when a positivity restriction to the control input is imposed. This positivity
restriction is made componentwise and corresponds to taking the control
input as u =
5
u1 · · · um
6T
with ui = max(u˜i, 0), where u˜i denotes the
i≠ th component of u˜. Note that u˜i = Ei(≠CAx+ ⁄(yú≠ y)), where Ei Ø 0
6
is the i≠ th entry of E. Therefore if u˜i < 0 then ≠CAx+⁄(yú≠ y) < 0, and
all the other components u˜j of u˜ corresponding to nonzero Ej are negative
as well. This allows to conclude that either u = u˜ or u = 0. In this latter
case
⁄(yú ≠ y) < CAx. (9)
Since, by assumption (A3), CA < 0 and x Ø 0, then CAx Æ 0 and (9)
implies that yú ≠ y < 0.
To prove that all trajectories converge to yú, we apply the LaSalle’s in-
variance principle (see LaSalle [12], Leine and Wouw [13], Liao et al. [14],
Bullo [15]) to the Lyapunov function
V (x) = 12(y
ú ≠ y)2 (10)
for the system (1) on Rn+.
For u = u˜:
V˙ (x) = ≠(yú ≠ y)y˙ = ≠(yú ≠ y)Cx˙ (11)
= ≠(yú ≠ y)C (Ax+B [E⁄(yú ≠ y)≠ ECAx]) (12)
= ≠⁄(yú ≠ y)(yú ≠ y) = ≠⁄(yú ≠ y)2 Æ 0 (13)
For u = 0 (which can only happen when yú ≠ y < 0, see (3)):
V˙ (x) = ≠(yú ≠ y)Cx˙ = ≠ (yú ≠ y)¸ ˚˙ ˝
<0
CAx¸ ˚˙ ˝
Æ0
Æ 0 (14)
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Thus
V˙ (x) =
Y_]_[ ≠⁄(y
ú ≠ y)2 for u = u˜
≠(yú ≠ y)CAx for u = 0
(15)
By the LaSalle’s invariance principle, all system trajectories converge to the
largest set contained in
W = {x œ Rn+ : V˙ (x) = 0}, (16)
which is forward-invariant under the closed-loop dynamics. It follows from
(15) that V˙ (x) = 0 either when u = u˜ and y = yú or when u = 0,which
implies yú < y, and CAx = 0. So we get
W = {x œ Rn+ : y = yú or (yú < y and CAx = 0)}. (17)
Moreover, the set  yú of positive states for which the corresponding out-
put y equals yú is forward-invariant under the closed-loop dynamics. In fact,
let F (x) be the vector field associated with the closed-loop system
Y_]_[ x˙ = Ax+Buu = max(u˜, 0). (18)
When Cx = yú, u = u˜ = ≠ECAx Ø 0 and F (x) = Ax ≠ BECAx. As a
consequence, recalling that CBE = 1, one obtains CF (x) = 0 showing that
F (x) is tangent to  yú . So  yú is forward-invariant under the closed-loop
dynamics.
On the other hand, the trajectories starting in a state x for which Cx > yú
and CAx = 0 converge to  yú , because
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Cx > yú ∆ u = 0 (19)
∆ x˙(t) = Ax(t). (20)
Since A is assumed to be stable, if the control would remain zero, then
limtæŒCx(t) would be zero. This implies that at a certain time instant,
say tú, Cx(tú) reaches the value Cx(tú) = yú, i.e. x(tú) œ  yú . From this
instant on the trajectories remain indefinitely in the forward-invariant set
 yú . Therefore, the largest invariant subset contained in W is  yú and, by
LaSalles’s invariance principle, all the closed-loop system trajectories con-
verge to this set, which means that limtæŒ y(t) = yú as desired.
The study just developed leads to the following result.
Theorem 1. Let (A,B,C) be a positive MISO linear system, such that A
is stable, CA < 0 and CB ”= 0. If u = max(u˜, 0), u˜ = ≠ECAx + E⁄(yú ≠
y), with ⁄ > 0, and E Ø 0 such that CBE = 1, then the closed-loop system
output y(t) verifies limtæŒ y(t) = yú.
3. CONTROL OF THE DEPTH OF ANESTHESIA
Combinations of drugs are used in general anesthesia because no single
drug is able to provide all its necessary components (namely, analgesia, hyp-
nosis, areflexia) without seriously compromising hemodynamic and/or res-
piratory function, impairing operating conditions, or delaying postoperative
recovery. Ideal combination of dosing facilitates optimal therapeutic e ect
without producing significant side e ects.
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Here, a control law is designed to administer the hypnotic agent propofol
and the opioid analgesic remifentanil to patients during surgery, in order to
achieve a desired level of unconsciousness. This is measured in terms of the
depth of anesthesia (DoA), usually denoted by z(t), which is a feature that
can be related to the quantities of administered drugs as explained next.
In what concerns DoA, the response to the administration of hypnotics
and analgesics is commonly modeled as a high order pharmacokinetic/phar-
macodynamic (PK/PD) Wiener model (see Bailey and Haddad [16]). How-
ever, a new Wiener model (parameter parsimonious Wiener model) with a
reduced number of parameters describing the join e ect of propofol and of
remifentanil as been introduced in Silva et al. [10]. Here, the main goal of
this section is to design a controller for the DoA based on this parameter
parsimonious Wiener model.
The e ect concentration of propofol (cpe) and of remifentanil (cre) can be
modeled by the parameter parsimonious Wiener model developed by Silva
et al. [10]. According to this model
cpe(s) =
k1k2k3–3
(k1–+ s)(k2–+ s)(k3–+ s)
up(s), (21)
cre(s) =
l1l2l3÷3
(l1÷ + s)(l2÷ + s)(l3÷ + s)
ur(s), (22)
where cpe(s), cre(s) denote the Laplace transforms of cpe(t) and cre(t), respec-
tively, and up(s) and ur(s) are the Laplace transforms of the administered
doses of propofol, up(t), and of remifentanil, ur(t), in mgmin≠1. Each of
10
the transfer functions in (21) and (22) has three aligned poles, more con-
cretely, the first one has poles (≠k1,≠k2,≠k3)– and the second one has poles
(≠l1,≠l2,≠l3)÷. The parameters kj, lj, j = 1, 2, 3 were chosen in Silva et al.
[10] according to the collected patient data and fixed at the values k1 = 10,
k2 = 9, k3 = 1, l1 = 3, l2 = 2, l3 = 1. The parameters – and ÷ are patient
dependent.
The joint e ect of the concentrations of propofol and remifentanil on the
BIS level is modelled in Silva et al. [10] by the generalized Hill equation:
z(t) = z01 + (µUp + U r)“ , (23)
where µ, “ are patient dependent parameters, z0 is the e ect at zero con-
centration, and Up and U r respectively denote the potencies of propofol and
remifentanil, which are obtained by normalizing the e ect concentrations
with respect to the concentrations that produce half the maximal e ect when
the drug acts isolated (denoted by ECp50 and ECr50, respectively), i.e.:
Up = c
p
e
ECp50
and U r = creECr50 . (24)
In this work we consider – œ [0.03 , 0.17], ÷ œ]0 , 5.70], ECp50 = 10 and
ECr50 = 0.01. The values of ECp50 = 10 and ECr50 = 0.01 are taken from
Mendonc¸a et al. [17] and the intervals for the values of – and ÷ are obtained
as follows: – œ [–¯ ≠ 2‡– , –¯ + 4‡–] and — œ]0 , —¯ + 4‡—], where –¯ and
‡– respectively denote the mean and standard deviation of the parameters
identified in Mendonc¸a et al. [17], and ÷¯ and ‡÷ have the obvious meaning,
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now for the parameter ÷. The choice of lower bound 0 for ÷ is due to the fact
that ÷ should be positive and ÷¯ ≠ 2‡÷ < 0.
The transfer functions in (21) and (22) can be represented by the follow-
ing state-space model:
Y_]_[
x˙i = Aixi +Biui
cie =
5
0 0 1
6
xi, i = p, r
(25)
where
xi =
SWWWWWU
xi1
xi2
xi3
TXXXXXV is the state,
Ap =
SWWWWWU
≠10– 0 0
9– ≠9– 0
0 – ≠–
TXXXXXV , Ar =
SWWWWWU
≠3÷ 0 0
2÷ ≠2÷ 0
0 ÷ ≠÷
TXXXXXV ,
Bp =
SWWWWWU
10–
0
0
TXXXXXV and Br =
SWWWWWU
3÷
0
0
TXXXXXV .
(26)
Defining U = µUp + U r yields
z(t) = z01 + U“ , (27)
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with
U = 1
ECp50
µcpe +
1
ECr50
cre = 0.1µcpe + 100cre. (28)
This leads to the following model
Y_____]_____[
x˙(t) = Ax(t) +Bu(t)
U(t) = 0.1µcpe(t) + 100cre(t) = Cx(t)
z(t) = z01+U“ ,
(29)
where
x(t) =
SWU xp(t)
xr(t)
TXV , A =
SWU Ap 03◊3
03◊3 Ar
TXV ,
B =
SWU Bp 03◊1
03◊1 Br
TXV , C = 5 0 0 0.1µ 0 0 100 6 .
(30)
As mentioned before, for surgery purposes it is desirable to maintain the
BIS close to a certain reference level zref between 40 and 60. This can be
achieved by designing a control law that forces U(t) to follow the constant
reference level
U ref = “
Ú
z0
zref
≠ 1. (31)
In order to apply the design method of the previous subsection, the prod-
uct CB should be a nonzero row. However, here CB =
5
0 0
6
and the
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condition is not met. To overcome this problem, instead of the output U(t),
the output
M(x(t)) = 0.1Mp(xp(t)) + 100M r(xr(t)) = CMx(t), (32)
with
Mp(xp) =
5
1 1 1
6
xp, M r(xr) =
5
1 1 1
6
xr and
CM =
5
0.1 0.1 0.1 100 100 100
6
, (33)
is considered. The notationsM(x(t)),Mp(xp(t)), and M r(xr(t)) are inspired
by the fact that, in compartmental systems, the sum of the state components
usually corresponds to the total substance mass present in the system. As we
shall later see, a connection between the reference value U ref and an adequate
reference value M ref for M can be established, in such a way that when
limtæŒM(x(t)) =M ref then limtæŒ U(t) = U ref and limtæŒ z(t) = zref , as
desired.
In a first stage we show that every positive constant reference value Mú
for M (x(t)) can be tracked using a control law as proposed in Theorem 1.
Then, in a second step, we determine which value should be taken forMú
in order to ensure that the desired constant reference value zref for the BIS
level is achieved.
Since now, for the new output matrix CM , defined in (33), CMB =5
– 300÷
6
is nonzero, the applicability of the proposed controller design
method is guaranteed.
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Proposition 1. Let (A,B,CM) be a positive MISO linear system, with A,
B as in (30) and CM as in (33). Define
E =
SWU ﬂ
1
TXV 1
–ﬂ+ 300÷ , (34)
where ﬂ > 0 is an arbitrary nonnegative value. Then, applying the control
law
u = max(0, u˜), (35)
with
u˜ =
SWU u˜p
u˜r
TXV = E (≠CMAx+ ⁄(Mú ≠M)) and ⁄ > 0 (36)
=
SWU ﬂ
1
TXV (≠CMAx+ ⁄(Mú ≠M)) 1
–ﬂ+ 300÷¸ ˚˙ ˝
u¯
, (37)
and ⁄ > 0
to the system (A,B,CM), yields limtæŒM(x(t)) =Mú.
Proof. Since CMBE = 1, all the conditions of Theorem 1 are satisfied yield-
ing the desired result.
Remark: Note that, in this control law, ⁄ and ﬂ are design parameters.
Moreover
SWU u˜p
u˜r
TXV =
SWU ﬂ
1
TXV u¯, with u¯ as in (37), meaning that the proportion
of propofol and remifentanil is ﬂ : 1.
Since the choice of the positive parameter ﬂ does not a ect the tracked
reference value, this may constitute an advantage, as it allows to choose
15
the proportion between the two drugs, in order to accommodate clinical
restrictions or considerations, without significant consequences in terms of
the e ect. This will be illustrated later on in the simulations.
In order to determine which value of M ref should be chosen for Mú in
the control law (37) to guarantee that the BIS level z(t) tracks a desired
constant value zú, an analysis is made of the values U(t) obtained for the
closed-loop system. For this purpose it will be first proved that the state
of the closed-loop system (A,B,CM) with the control law (35) converges to
an equilibrium point xú. To show this, since, as mentioned in the previous
section, the trajectories x(t) converge to the forward-invariant set  Mú =
{x œ R6+ : M(x) = Mú}, it is enough to prove that, for the restriction
of the closed-loop system to this set, the state trajectories converge to an
equilibrium point xú. Note that this restriction is well defined as  Mú is
forward-invariant under the closed-loop dynamics.
In order to obtain the dynamics of the system restricted to  Mú , note that
when x œ  Mú , i.e., whenM(x) =Mú, the control u˜ is given by u˜ = ≠ECAx,
and the closed-loop system can be described as
x˙ = A˜x (38)
with
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A˜ = A≠BECMA
=
SWWWWWWWWWWWWWWWU
a1 ≠ 10– 8a1 a1 a2 a2 a2
9– ≠9– 0 0 0 0
0 – ≠– 0 0 0
a3 8a3 a3 a4 ≠ 3÷ a4 a4
0 0 0 2÷ ≠2÷ 0
0 0 0 0 ÷ ≠÷
TXXXXXXXXXXXXXXXV
where
a1 = –2ﬂe, a2 = 1000–÷ﬂe,
a3 = 0.3–÷e, a4 = 300÷2e,
e = 1–ﬂ+300÷
and A,B,CM and E are given by (30), (33), and (34).
In order to analyze the stability of the closed-loop system restricted to
 Mú , the evolution equations of this restriction are next obtained.
When M(x(t)) =Mú,
xp1(t) =Mú ≠ xp2(t)≠ xp3(t)≠ 1000(xr1(t) + xr2(t) + xr3(t)). (39)
Replacing this in the equation and x˙(t) = A˜x(t) yields
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Y___________________]___________________[
x˙p1(t) = Mú ≠ x˙p2(t)≠ x˙p3(t)≠ x˙r1(t)≠ x˙r2(t)≠ x˙r3(t)
x˙p2(t) = 9–(Mú ≠ xp2(t)≠ xp3(t)≠ 1000(xr1(t) + xr2(t) + xr3(t)))≠ 9–xp2(t)
x˙p3(t) = –xp2(t)≠ –xp3(t)
x˙r1(t) = a3Mú + 7a3xp2(t) + (a4 ≠ 1000a3 ≠ 3÷)xr1(t)+
+(a4 ≠ 1000a3(xr2(t) + xr3(t))
x˙r2(t) = 2÷xr1(t)≠ 2÷xr2(t)
x˙r3(t) = ÷xr2(t)≠ ÷xr3(t).
(40)
Since the state component xp1(t) can be obtained from the others state com-
ponents (see (39)), we can conclude that the closed-loop system dynamics
restricted to  Mú is described by the evolution of the vector
x¯ =
SWWWWWWWWWWWWU
xp2
xp3
xr1
xr2
xr3
TXXXXXXXXXXXXV
, (41)
which is given by the last five equations from (40). These equations can
be written in matrix form as:
˙¯x = A¯x¯+R, (42)
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with
A¯ =
SWWWWWWWWWWWWU
≠18– ≠9– ≠9000– ≠9000– ≠9000–
– ≠– 0 0 0
7a3 0 a4 ≠ 1000a3 ≠ 3÷ a4 ≠ 1000a3 a4 ≠ 1000a3
0 0 2÷ ≠2÷ 0
0 0 0 ÷ ≠÷
TXXXXXXXXXXXXV
and
R =
SWWWWWWWWWWWWU
9–Mú
0
a3Mú
0
0
TXXXXXXXXXXXXV
.
Moreover, equation (42) can be written in the form:
‰˙x¯≠ x¯ú= A¯(x¯≠ x¯ú), (43)
where
x¯ú =
SWWWWWWWWWWWWU
ﬂ
ﬂ
1
1
1
TXXXXXXXXXXXXV
Mú
3(0.1ﬂ+ 100) (44)
is the only equilibrium point of (42), i.e., the only point such that x¯(t) © x¯ú
satisfies ˙¯x = A¯x¯(t) + R, as ˙¯x(t) = 0 and A¯x¯ú = ≠R. This can be verified by
performing the corresponding multiplication A¯x¯ú and checking that the result
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equals ≠R. Moreover, the uniqueness of x¯ú follows from the invertibility of
A¯ for the considered parameter range.
As is shown in Fig. 1, where the locations of the eigenvalues of A¯ are
plotted for the di erent value combinations of the parameters – and ÷, within
the ranges in this paper, and for ﬂ œ [0 , 500], the matrix A¯ is stable, i.e.,
all its eigenvalues have negative real part. The restriction ﬂ œ [0 , 500] is
only imposed to limit the high computation level, however this feat is not
a limitation to the applicability of the controller here proposed, since the ﬂ
values observed in the collected clinical cases are included in the considered
interval. Thus, x¯(t) converges to x¯ú = (ﬂ, ﬂ, 1, 1, 1) Mú3(0.1ﬂ+100) . Recalling that
equation (39) holds, this implies that x(t) = (xpú1 , x¯ú) with
xpú1 =Mú ≠
5
1 1 100 100 100
6
x¯ú (45)
= ﬂM
ú
3(0.1ﬂ+ 100) . (46)
Thus x(t) converges to xú = (ﬂ, ﬂ, ﬂ, 1, 1, 1) Mú3(0.1ﬂ+100) under the closed-
loop dynamics.
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Figure 1: Location of the eigenvalues of the matrix A¯, for the di erent value combinations
of the parameters –, ÷ and ﬂ within the ranges in this paper, i.e., – œ [0.03 , 0.17],
÷ œ]0 , 5.70], ﬂ œ [0 , 500]
Recalling that u(t) = 0.1µxp3(t)+ 100xr3(t), one concludes that, under the
closed loop dynamics,
Uú = lim
tæŒU(t) = 0.1µ limtæŒx
p
3(t) + 100 limtæŒx
r
3(t) (47)
= 0.1µ ﬂM
ú
3(0.1ﬂ+ 100) + 100
Mú
3(0.1ﬂ+ 100) (48)
=Mú 0.1µﬂ+ 1003(0.1ﬂ+ 100) . (49)
Consequently, in order to track a constant reference level U ref for U(t) it
is enough to take
Mú =M ref = 3(0.1ﬂ+ 100)0.1µﬂ+ 100 U
ref (50)
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in the control law (35).
Together with expression (31), these considerations lead to the following
result.
Proposition 2. Let (A,B,CM) be a positive MISO linear system, with A,
B as in (30) and CM as in (33). Then, applying the control law u as in (35),
with Mú = M ref = 3(0.1ﬂ+100)0.1µﬂ+100 “
Ò
z0
zref ≠ 1, to the system (A,B,CM), achieves
tracking of the constant reference value zref for the BIS level z(t) defined as
in (23), i.e., limtæŒ z(t) = zref .
Proof. It follows from what has just been said that taking in (35)
Mú =M ref = 3(0.1ﬂ+ 100)0.1µﬂ+ 100
“
Ú
z0
zref
≠ 1
achieves tracking of the constant reference value for U :
U ref = “
Ú
z0
zref
≠ 1.
The result now follows from expression (31).
As stated in Proposition 2, once the values of “ and µ are known for a
particular patient, the value of M ref to be considered in the control law is:
M ref = 3(0.1ﬂ+ 100)0.1µﬂ+ 100
“
Ú
z0
zref
≠ 1, (51)
where z0 = 97.7 and zref is the desired BIS level. Here it is assumed that the
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values of “ and µ are available, however, if this is not the case, these values
can be identified in a first stage, before turning on the controller. Another
possibility is to start with an average value for “ and µ and hence Mú as a
first estimate and then retune this value after “ and µ are more accurately
identified. A similar procedure was used in Nogueira et al. [18]. Here, it is
also assumed that the values of the parameters –, ÷ are known. This does
not happen in practice. However, in a real situation the controller action
only starts after an initial drug bolus is given. This is a current practice
with other automatic controllers previously used in clinical environment and
allows to identify the parameters for patient model.
4. CONTROLLER PERFORMANCE
In this section the performance of the control law presented in the previ-
ous sections is illustrated by means of several simulations. For this purpose,
we consider: z0 = 97.7; – = 0.0759; ÷ = 0.583; µ = 1.79; “ = 1.88. These pa-
rameter values are the mean values used in the work developed in Mendonc¸a
et al. [17], to which we refer for further explanation. We also assume that it
is intended that the DoA of a patient, corresponds to the reference value of
50 for the BIS signal. By (31), this means that U must follow the reference
Uú = 0.9753. Once these values are fixed, the control law only depends on
the design parameters ⁄ > 0 and ﬂ Ø 0. The parameter ⁄ influences the
speed of convergence to the reference value, as can be seen in Fig. 2 where
the values ⁄ = 0.02,⁄ = 1 were respectively taken for a fixed value of ﬂ = 2
(corresponding to proportion of 2 : 1 for propofol and remifentanil).
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Figure 2: Evolution of DoA, for ﬂ = 2,⁄ = 0.02 and ⁄ = 1.
On the other hand the parameter ﬂ specifies the desired proportion be-
tween the administered amounts of propofol and remifentanil, which may
be chosen according to clinical criteria. Figure 3 illustrates DoA e ect for
di erent drug proportions (namely, ﬂ = 0, ﬂ = 2, and ﬂ = 10) and Figures
4, 5, and 6 present the evolution of the corresponding drug dosages. As can
be seen in Fig. 3, in spite of the variation of the drug proportion (ﬂ) the
desired e ect is practically the same. It turns out that this may constitute an
advantage, since the choice of the proportion can be made in order to accom-
modate individual clinical restrictions or considerations, without significantly
consequences in terms of the e ect.
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Figure 3: Evolution of DoA for di erent values of drugs proportion, i.e., ﬂ = 0, ﬂ = 2, ﬂ =
10 and for ⁄ = 1.
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Figure 4: Evolution of the dosage of propofol and of remifentanil, for ⁄ = 1, ﬂ = 0 (without
propofol infusion dose).
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Figure 5: Evolution of the dosage of propofol and of remifentanil, for ⁄ = 1, ﬂ = 2.
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Figure 6: Evolution of the dosage of propofol and of remifentanil, for ⁄ = 1, ﬂ = 10.
Figure 7 illustrates the performance of the control algorithm in the pres-
ence of a change of the reference profile. In the first thirteen minutes it
is intended that the BIS follows the reference 50, in the following thirteen
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minutes the BIS reference level is set to 30 and in the last twenty minutes
the BIS should again follow the reference level 50. It may be seen that the
controller has a good performance also in this case. As expected, when the
reference decreases there is a small bolus of propofol and remifentanil, in
order to follow the reference, and when it increases no drug is administered.
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Figure 7: Evolution of DoA and of the dosages of propofol and of remifentanil, assuming
changes in the reference profiles (zú = 50 from the beginning till t = 30min, zú = 30 from
t = 30min till t = 60min, and zú = 50 from then on), for ⁄ = 1, ﬂ = 2.
In a real clinical environment, the measurements of the patients BIS levels
usually present a high level of noise, due to the nature of the sensors and the
physiological ineheretic signs. This fact implies the existence of noise in the
estimation of the states in the corresponding theoretical model. In Fig. (8)
the evolution of the DoA of a patient is illustrated in the presence of noise
in the measurement of the BIS level, that mimics the real data collected in
the surgery room. For this purpose, a normal distribution N(µnoise,‡noise),
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where µnoise = 0 and ‡noise = 3 are respectively the mean and the standard
deviation, was used. As we can see, in spite of the presence of noise in the
BIS measurements, the behavior of the controlled output of the patient is
clinically accepted.
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Figure 8: Evolution of DoA in the presence of noise, for ﬂ = 2 and ⁄ = 1.
5. A realistic simulation study
As a necessary preliminary step before implementation in clinical environ-
ment, the performance of the controller proposed in this paper is tested on a
bank of realistic simulated patients. These patients are simulated by means
of PK/PD Wiener models (see Marsh et al. [19], and Minto et al. [20]) ob-
tained from real data collected during eighteen breast surgeries. The patients
(all female, with 54± 13 years of age, a height of 160± 5cm, and 69± 18Kg)
were subject to general anesthesia under propofol and remifentanil adminis-
tration. The DoA was monitored by the BIS and was manually controlled
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around clinically accepted values by the anesthetist. Alaris GH pumps were
used for both propofol and remifentanil. Infusion rates, BIS values and other
physiological variables were acquired every five seconds (Mendonc¸a et al.
[17]).
For each patient, the corresponding PK/PD Wiener model was obtained
as follows. The parameters of the linear part were computed according to
Marsh et al. [19], Minto et al. [20], and Schnider et al. [21] based on the rel-
evant patient characteristics, whereas the parameters of the nonlinear part
(generalized Hill equation) were identified from the surgery data, by Men-
donc¸a et al. [17]. In order to test the proposed control strategy, each simu-
lated patient is also modeled by the parsimonious parameter Wiener model
of Silva et al. [10], with parameters identified as in Mendonc¸a et al. [17],
and a control law of the form (37) tuned for that model is applied to the
simulated patient. The set of parameter values identified by Mendonc¸a et al.
[17] is given in appendix A, where also the corresponding relevant patient
features that allow to compute the PK/PD model parameters are displayed.
Here we present the results obtained for patients 9 and 15 of the database
in two di erent simulations settings respectively. Patient 9 is a woman,
with 51 years of age, a height of 163cm, and with 55kg. The corresponding
identified parameters were: ECp50 = 12.17, ECr50 = 0.031, “ = 1.86, µ = 3.84,
– = 0.07, and ÷ = 0.28. Patient 15 is a woman, with 73 years of age, a
height of 160cm, a weight of 75kg, for which the identified parameters were:
ECp50 = 12.41, ECr50 = 0.016, “ = 1.68, µ = 3.47, – = 0.10, and ÷ = 0.04.
Figure 9 shows the BIS response of the patient 15 to the drug doses
administered by the anesthetist during the surgery, along with the response
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of the corresponding PK/PD model to the same drug input. The similarity
between the two responses supports the idea of using the identified PK/PD
models in order to simulate real patients.
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Figure 9: BIS response of the patient 15 (upper plot) to the drug doses administered by the
anesthetist during the surgery (lower plot), along with the response of the corresponding
PK/PD model to the same drug input. The average doses of propofol and of remifentanil
reported were 4.21mgmin≠1 and 0.0147mgmin≠1 respectively. Notice that propofol doses
above 30mgmin≠1 are not represented in the graphic.
In Fig. 10 the BIS response of the simulated patient 15 is presented, where
the DoA control was performed using the control law (37) for tracking a BIS
level of 50; this is an approximation value of the average real BIS obtained
throughout the surgery. The selected proportion between the two drugs was
the corresponding average reported in the monitored real case, ﬂ = 286.
The average of the doses of propofol and of remifentanil obtained by the
controller were respectively 4.27mgmin≠1 and 0.0149mgmin≠1; these values
are quite close to the reported real ones, 4.21mgmin≠1 and 0.0147mgmin≠1
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respectively. The obtained set-point for the BIS level was 54.7, presenting
an relative error of only 9%.
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BIS evolution of the simulated patient 15
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Figure 10: BIS response of the patient 15 and the infusion doses of propofol and of remifen-
tanil obtained by the proposed control law, for zú = 50, ﬂ = 286, and ⁄ = 10. The
average doses of propofol and of remifentanil obtained by the controller were respectively
4.27mgmin≠1 and 0.0149mgmin≠1. Notice that propofol doses above 30mgmin≠1 are
not represented in the graphic.
Figure 11 illustrates the application of the proposed control law to all the
18 simulated patients, for a desired reference BIS level of 50 (the remaining
parameters are presented in the figure). As can be seen, the desired BIS level
obtained in all the cases are very close to the desired one.
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Figure 11: BIS response of all eighteen simulated patients (by means of a PK/PD model)
controlled by the proposed control law, tuned for the corresponding parameter parsimo-
nious model, for zú = 50, ﬂ = 2, and ⁄ = 10.
In Fig. 12 the performance of the control in the presence of a change of
the reference profile and in the value of drugs proportion is illustrated (for
patient 9). In the first ninety minutes it is intended that the BIS follows
the reference 50, in the following thirty minutes the BIS reference level is set
to 40 and in the last forty minutes the BIS is regulated to follow again the
reference level 50. As expected, a reference decrease produces a peak in the
doses of propofol and remifentanil, whereas when the reference increases no
drug is administered. The proportion between the two drugs was ﬂ = 0.2 in
the first forty minutes and from then on it was changed to ﬂ = 3. In spite
of the variation of the drug proportion the BIS follows the desired reference.
The possibility of changing the drug proportion during the surgery without
a ecting the reference tracking results constitutes a considerable advantage.
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Indeed, clinical practice has often shown the need of adjusting the dosage
profile according to the overall physiological response of the patient.
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Figure 12: Evolution of DoA, of patient 9, and of the dosages of propofol and of remifen-
tanil, assuming changes in the reference profiles (zú = 50 from the beginning till t = 90min,
zú = 40 from t = 90min till t = 120min, and zú = 50 from then on) and assuming changes
in the value of the drugs proportions (ﬂ = 0.2 in the first forty minutes and from then on
it was changed to ﬂ = 3). ⁄ = 1.
6. Conclusion
A positive control law for multi-input positive systems was proposed in
order to track a desired output reference value. This controller was applied in
the control of the DoA, tracking the BIS level for a certain designed profile,
by means of simultaneous administration of propofol and remifentanil, based
on the parsimonious parameter model. This new Wiener model describes the
joint e ect of these two drugs and is adequate for model based control design
since it presents a reduced number of parameters.
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In this work it was theoretically proved that the controller may be tuned in
order to achieve di erent convergence rates and di erent desired proportions
between the dosages of these two drugs, in order to obtain a certain reference
value for the BIS. Moreover, this controller also provides the possibility of
changing the drugs proportion during the surgical anesthetic procedure with-
out a ecting the reference tracking results, which constitutes an interesting
clinical advantage. Indeed anesthetic procedures during surgery relies on a
defined DoA profile, but the change of the dosage profile due to the overall
physiological response of the patient is often required.
The performance of the controller proposed in this paper was tested with
success, by several simulations, on a bank of realistic simulated patients sim-
ulated by means of PK/PD Wiener models obtained from real data collected.
The simulation study illustrates the performance of the proposed controller
under a variety of clinical conditions, like presence of noise measurement,
changing of the doses proportions and of the reference profile.
References
[1] L. Farina, S. Rinaldi, Positive Linear Systems: Theory and Applica-
tions., John Wiley & Sons, 2000.
[2] W. M. Haddad, T. Hayakawa, J. M. Bailey, International journal of
adaptative control and signal processing (2003) 17: 209–235 (DOI:
10.1002/acs.737).
[3] B. Roszak, E. J. Davison, Proceedings of Workshop on Recent Advances
in Control and Learning LNCIS 371 (2008) 181–193.
34
[4] B. Roszak, E. J. Davison, IEEE Transactions on Automatic Control
55(9) (Sept. 2010) 2204–2209.
[5] T. Kaczorek, Positive 1D and 2D systems, Springer, London, 2002.
[6] J. C. Willems, Journal Automatica (Journal of IFAC) 12(5) (Sept. 1976)
519–523.
[7] K. Soltesz, G. A. Dumont, K. Heusden, T. Ha¨gglund, 51st IEEE Con-
ference on Decision and Control (Dec. 2012).
[8] G. Bastin, A. Provost, in: Proceedings of the 15th International Sym-
posium on Mathematical Theory of Networks and Systems (2002).
[9] G. Dumont, Proceedings of the 8th IFAC Symposium on Biological and
Medical Systems (2012) (2012).
[10] M. M. Silva, T. Mendonc¸a, T. Wigren, Proceedings of the American
Control Conference (ACC10) (2010) 4379– 4384.
[11] K. Godfrey, Compartmental Models and Their Application, Academic
Press, 1983.
[12] J. P. LaSalle, The Stability of Dynamical Systems, SIAM, Bristol, Eng-
land, 1976.
[13] R. I. Leine, N. Wouw, Stability and Convergence of Mechanical Systems
with Unilateral Constraints, Springer-Verlag, German, 2008.
[14] X. Liao, L. Wang, P. Yu, Stability of Dynamical Systems, Elsevier,
Netherlands, 2007.
35
[15] F. Bullo, Geometric Control of Mechanical Systems, Springer, USA,
2005.
[16] J. M. Bailey, W. M. Haddad, Control Systems Magazine, IEEE 25 (2005)
35 – 51.
[17] T. Mendonc¸a, H. Alonso, M. M. Silva, S. Esteves, M. Seabra, 16th IFAC
Symposium on System Identification (2012).
[18] F. N. Nogueira, T. Mendonc¸a, P. Rocha, Proceedings of the 21st
Mediterranean Conference on Control and Automation (MED’13)
(2013).
[19] B. Marsh, N. Norton, G. N. Kenny, Br. J. Anaesthesia 67 (1991) 41 –
48.
[20] C. F. Minto, T. W. Schnider, T. D. Egan, E. Youngs, H. J. Lemmens,
P. L. Gambus, V. Billard, J. F. Hoke, K. H. Moore, D. J. Hermann,
K. T. Muir, J. W. Mandema, S. L. Shafer, Anesthesiology 86 (1997) 10
– 23.
[21] T. W. Schnider, C. F. Minto, P. L. Gambus, C. Andresen, D. B. Goodale,
S. L. Shafer, E. J. Youngs, Anesthesiology 8 (1998) 1170 – 1182.
Appendix A. Database
This database was courteously provided by Galeno project (http://www2.fc.up.pt/galeno/).
The parameters presented in Table A.2 were identified in Mendonc¸a et al.
[17].
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Table A.1: Patient features
Gender Age Height (cm) Weight (kg)
Patient 1 F 56 160 88
Patient 2 F 48 158 52
Patient 3 F 51 165 55
Patient 4 F 56 160 65
Patient 5 F 64 146 60
Patient 6 F 59 159 110
Patient 7 F 29 163 59
Patient 8 F 45 155 58
Patient 9 F 51 163 55
Patient 10 F 32 172 56
Patient 11 F 68 160 64
Patient 12 F 50 161 68
Patient 13 F 68 158 113
Patient 14 F 70 161 78
Patient 15 F 73 160 75
Patient 16 F 34 162 57
Patient 17 F 43 155 62
Patient 18 F 66 155 74
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Table A.2: PPM Parameters
– ÷ “ µ
Patient 1 0.0667 0.3989 2.0321 4.3266
Patient 2 0.0874 0.0670 1.0133 4.3845
Patient 3 0.0693 0.0482 2.0196 3.3133
Patient 4 0.0590 0.0425 1.8930 4.2273
Patient 5 0.0489 0.1269 1.0702 3.9505
Patient 6 0.0677 0.3373 2.6169 4.3774
Patient 7 0.0737 0.2793 3.7297 4.1494
Patient 8 0.0860 0.0212 0.9172 1.0000
Patient 9 0.0701 0.2837 1.8645 3.8367
Patient 10 0.1041 0.1038 1.4517 3.7978
Patient 11 0.0343 3.5768 0.9334 4.4496
Patient 12 0.0467 0.1254 1.6649 4.2860
Patient 13 0.0687 4.5413 0.9882 3.8094
Patient 14 0.0774 0.0397 3.8213 3.2302
Patient 15 0.0995 0.0377 1.6771 3.4726
Patient 16 0.0929 0.1205 3.9302 3.9983
Patient 17 0.0811 0.1033 1.6096 4.2064
Patient 18 0.1336 0.2307 1.5613 4.2411
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